RVMD
HealthcareRevolution Medicines, Inc.
$78.33
$-0.69 (-0.87%)
Jan 5, 2026
Price History (1Y)
Analysis
Revolution Medicines, Inc. is a biotechnology company in the healthcare sector with a significant scale, boasting a market capitalization of $15.14 billion and 809 employees. The company's financial health is marked by substantial losses, with net income totaling -$960,977,984 and EBITDA at -$1,029,836,992 for the trailing twelve months. Additionally, Revolution Medicines has negative profitability margins, including a gross margin of 0.0%, operating margin of 0.0%, and profit margin of 0.0%. The company's returns on equity and assets are also negative, at -60.8% and -32.3%, respectively. In terms of its balance sheet, Revolution Medicines has $414.97 million in debt and $1.93 billion in cash. The company's valuation is characterized by a forward P/E ratio of -12.49 and an EV/EBITDA ratio of -13.36. The price to book ratio is 9.31, indicating the market's perception of Revolution Medicines' value relative to its assets.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Visit website →Key Statistics
- Market Cap
- $15.14B
- P/E Ratio
- N/A
- 52-Week High
- $81.97
- 52-Week Low
- $29.17
- Avg Volume
- 2.29M
- Beta
- 0.99
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 809